TY - JOUR
T1 - Streptozocin-induced diabetes mellitus in the pregnant ewe
AU - Dickinson, Jan E.
AU - Meyer, Bruce A.
AU - Chmielowiec, Susie
AU - Palmer, Sue M.
PY - 1991/12
Y1 - 1991/12
N2 - To evaluate the effects of streptozocin on maternal pancreatic β-cell function, we administered the agent to 14 pregnant ewes at 85 to 90 days' gestation on two occasions, 4 days apart. Intravenous glucose tolerance tests were performed before the initial administration, before the second dose, and 4 weeks after the final dose of streptozocin. There was a significant elevation in maternal fasting blood glucose (82 ± 8.1 mg/dl before streptozocin and 102.6 ± 6.8 mg/dl after streptozocin, p < 0.05). Five late-gestation ewes were used as controls, and a significant elevation in fasting plasma glucose levels was found in the streptozocin-treated animals (71.4 ± 7.1 mg/dl control vs 102.6 ± 6.8 mg/dl after streptozocin, p < 0.05). The glucose tolerance test curves showed a significant elevation 4 weeks after streptozocin compared with before streptozocin (p < 0.05). The maternal insulin response to streptozocin demonstrated a loss of the second-phase insulin response to the glucose load after one dose of streptozocin and loss of the first phase after two doses. The fetuses of the streptozocin-treated ewes showed a significant elevation in plasma glucose level compared with that of controls (13.3 ± 0.8 mg/dl, n = 5) vs 42.1 ± 8.1 mg/dl, n = 10; p < 0.05, control vs streptozocin, respectively). There was a consistent trend to fetal hyperinsulinemia in the fetuses of the streptozocin-treated ewes, although this did not achieve statistical significance (3.3 ± 0.8 μlU/ml, n = 5 vs 9.6 ± 2.5 μlU/ml, n = 10; p = 0.06, control vs streptozocin, respectively). The fetal insulin/glucose ratio was preserved in the streptozocin-treated ewes. Comparison of fetal weights between the control and diabetic ewes showed a significant increase in fetal weight in the fetuses of diabetic ewes (3280 ± 46 gm in control fetuses vs 3710 ± 54 gm in diabetic fetuses, p < 0.05). The alterations in the maternal glucose and insulin response resulting from streptozocin-induced pancreatic β-cell destruction combined with elevations in fetal glucose, insulin, and weight provides a large animal model suitable for investigation of gestational diabetes in pregnancy.
AB - To evaluate the effects of streptozocin on maternal pancreatic β-cell function, we administered the agent to 14 pregnant ewes at 85 to 90 days' gestation on two occasions, 4 days apart. Intravenous glucose tolerance tests were performed before the initial administration, before the second dose, and 4 weeks after the final dose of streptozocin. There was a significant elevation in maternal fasting blood glucose (82 ± 8.1 mg/dl before streptozocin and 102.6 ± 6.8 mg/dl after streptozocin, p < 0.05). Five late-gestation ewes were used as controls, and a significant elevation in fasting plasma glucose levels was found in the streptozocin-treated animals (71.4 ± 7.1 mg/dl control vs 102.6 ± 6.8 mg/dl after streptozocin, p < 0.05). The glucose tolerance test curves showed a significant elevation 4 weeks after streptozocin compared with before streptozocin (p < 0.05). The maternal insulin response to streptozocin demonstrated a loss of the second-phase insulin response to the glucose load after one dose of streptozocin and loss of the first phase after two doses. The fetuses of the streptozocin-treated ewes showed a significant elevation in plasma glucose level compared with that of controls (13.3 ± 0.8 mg/dl, n = 5) vs 42.1 ± 8.1 mg/dl, n = 10; p < 0.05, control vs streptozocin, respectively). There was a consistent trend to fetal hyperinsulinemia in the fetuses of the streptozocin-treated ewes, although this did not achieve statistical significance (3.3 ± 0.8 μlU/ml, n = 5 vs 9.6 ± 2.5 μlU/ml, n = 10; p = 0.06, control vs streptozocin, respectively). The fetal insulin/glucose ratio was preserved in the streptozocin-treated ewes. Comparison of fetal weights between the control and diabetic ewes showed a significant increase in fetal weight in the fetuses of diabetic ewes (3280 ± 46 gm in control fetuses vs 3710 ± 54 gm in diabetic fetuses, p < 0.05). The alterations in the maternal glucose and insulin response resulting from streptozocin-induced pancreatic β-cell destruction combined with elevations in fetal glucose, insulin, and weight provides a large animal model suitable for investigation of gestational diabetes in pregnancy.
KW - Diabetes
KW - ovine
KW - pregnancy
KW - streptozocin
UR - http://www.scopus.com/inward/record.url?scp=0026344211&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026344211&partnerID=8YFLogxK
U2 - 10.1016/0002-9378(91)90013-H
DO - 10.1016/0002-9378(91)90013-H
M3 - Article
C2 - 1836305
AN - SCOPUS:0026344211
SN - 0002-9378
VL - 165
SP - 1673
EP - 1677
JO - American journal of obstetrics and gynecology
JF - American journal of obstetrics and gynecology
IS - 6 PART 1
ER -